<!DOCTYPE html>
<html lang="zh-CN"><head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <meta name="generator" content="VuePress 2.0.0-beta.67">
    <style>
      :root {
        --c-bg: #fff;
      }
      html.dark {
        --c-bg: #22272e;
      }
      html, body {
        background-color: var(--c-bg);
      }
    </style>
    <script>
      const userMode = localStorage.getItem('vuepress-color-scheme');
			const systemDarkMode = window.matchMedia && window.matchMedia('(prefers-color-scheme: dark)').matches;
			if (userMode === 'dark' || (userMode !== 'light' && systemDarkMode)) {
				document.documentElement.classList.toggle('dark', true);
			}
    </script>
    
    <link rel="preload" href="/assets/style-556920d0.css" as="style"><link rel="stylesheet" href="/assets/style-556920d0.css">
    <link rel="modulepreload" href="/assets/app-ab70e89e.js"><link rel="modulepreload" href="/assets/Part2.html-9a144fb5.js"><link rel="modulepreload" href="/assets/Part2.html-37534361.js"><link rel="prefetch" href="/assets/index.html-72c9cbe8.js" as="script"><link rel="prefetch" href="/assets/Anti-Androgens.html-8d34972c.js" as="script"><link rel="prefetch" href="/assets/CONTACT.html-da15e753.js" as="script"><link rel="prefetch" href="/assets/DONATE.html-13da2327.js" as="script"><link rel="prefetch" href="/assets/Estradiol.html-060531b1.js" as="script"><link rel="prefetch" href="/assets/HOME.html-2fbfc837.js" as="script"><link rel="prefetch" href="/assets/HairLoss.html-41c59a73.js" as="script"><link rel="prefetch" href="/assets/Miscellaneous.html-38fdc816.js" as="script"><link rel="prefetch" href="/assets/Progesterone.html-1c28382d.js" as="script"><link rel="prefetch" href="/assets/index.html-3768c535.js" as="script"><link rel="prefetch" href="/assets/RESOURCES.html-45fb3291.js" as="script"><link rel="prefetch" href="/assets/SERMs.html-6f0a2e16.js" as="script"><link rel="prefetch" href="/assets/index.html-0f406bc5.js" as="script"><link rel="prefetch" href="/assets/index.html-9dbbe242.js" as="script"><link rel="prefetch" href="/assets/Part0.html-0efe7fce.js" as="script"><link rel="prefetch" href="/assets/Part1.html-ee601a6f.js" as="script"><link rel="prefetch" href="/assets/Part3.html-3cf0e13e.js" as="script"><link rel="prefetch" href="/assets/Part4.html-09b40aa3.js" as="script"><link rel="prefetch" href="/assets/Part5.html-c32b3765.js" as="script"><link rel="prefetch" href="/assets/Part6.html-0baff854.js" as="script"><link rel="prefetch" href="/assets/Part7.html-7fffb08e.js" as="script"><link rel="prefetch" href="/assets/index.html-d93e35fc.js" as="script"><link rel="prefetch" href="/assets/404.html-f9875e7b.js" as="script"><link rel="prefetch" href="/assets/index.html-ce4c1786.js" as="script"><link rel="prefetch" href="/assets/Anti-Androgens.html-a535073f.js" as="script"><link rel="prefetch" href="/assets/CONTACT.html-d006429e.js" as="script"><link rel="prefetch" href="/assets/DONATE.html-4ed85b82.js" as="script"><link rel="prefetch" href="/assets/Estradiol.html-1582d610.js" as="script"><link rel="prefetch" href="/assets/HOME.html-c7a4d9f5.js" as="script"><link rel="prefetch" href="/assets/HairLoss.html-20c57efa.js" as="script"><link rel="prefetch" href="/assets/Miscellaneous.html-2f3b8362.js" as="script"><link rel="prefetch" href="/assets/Progesterone.html-eb7d725c.js" as="script"><link rel="prefetch" href="/assets/index.html-9e1817f9.js" as="script"><link rel="prefetch" href="/assets/RESOURCES.html-b623884c.js" as="script"><link rel="prefetch" href="/assets/SERMs.html-8d2e4057.js" as="script"><link rel="prefetch" href="/assets/index.html-f45bee25.js" as="script"><link rel="prefetch" href="/assets/index.html-82519792.js" as="script"><link rel="prefetch" href="/assets/Part0.html-43d4958d.js" as="script"><link rel="prefetch" href="/assets/Part1.html-dab657d2.js" as="script"><link rel="prefetch" href="/assets/Part3.html-5766506c.js" as="script"><link rel="prefetch" href="/assets/Part4.html-90e366be.js" as="script"><link rel="prefetch" href="/assets/Part5.html-d63862c0.js" as="script"><link rel="prefetch" href="/assets/Part6.html-7678369a.js" as="script"><link rel="prefetch" href="/assets/Part7.html-ea9d7c1f.js" as="script"><link rel="prefetch" href="/assets/index.html-c9247adb.js" as="script"><link rel="prefetch" href="/assets/404.html-5f688d03.js" as="script">
  <style type="text/css">.medium-zoom-overlay{position:fixed;top:0;right:0;bottom:0;left:0;opacity:0;transition:opacity .3s;will-change:opacity}.medium-zoom--opened .medium-zoom-overlay{cursor:pointer;cursor:zoom-out;opacity:1}.medium-zoom-image{cursor:pointer;cursor:zoom-in;transition:transform .3s cubic-bezier(.2,0,.2,1)!important}.medium-zoom-image--hidden{visibility:hidden}.medium-zoom-image--opened{position:relative;cursor:pointer;cursor:zoom-out;will-change:transform}</style><link rel="icon" href="/favicon.ico"><link rel="stylesheet" href="/custom.css" type="text/css"><title>Part 2 雌激素 (Estrogens) | GAHT Guide</title><meta name="description" content="GAHT Guide for transfemale"></head>
  <body>
    <div id="app"><!--[--><div class="theme-container"><!--[--><header class="navbar"><div class="toggle-sidebar-button" title="toggle sidebar" aria-expanded="false" role="button" tabindex="0"><div class="icon" aria-hidden="true"><span></span><span></span><span></span></div></div><span><a href="/" class=""><img class="logo" src="/logo.png" alt="GAHT Guide"><span class="site-name can-hide">GAHT Guide</span></a></span><div class="navbar-items-wrapper" style="max-width: 1687px;"><!--[--><!--]--><nav class="navbar-items can-hide"><!--[--><div class="navbar-item"><a href="/" class="" aria-label="首页"><!--[--><!--]--> 首页 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/menu/" class="" aria-label="目录"><!--[--><!--]--> 目录 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/cafe/" class="" aria-label="Cafe"><!--[--><!--]--> Cafe <!--[--><!--]--></a></div><div class="navbar-item"><a href="/tools/" class="" aria-label="工具"><!--[--><!--]--> 工具 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/link/" class="" aria-label="链接"><!--[--><!--]--> 链接 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/credits/" class="" aria-label="Credits"><!--[--><!--]--> Credits <!--[--><!--]--></a></div><div class="navbar-item"><a class="external-link" href="https://github.com/BBleae/hrt-book" rel="noopener noreferrer" target="_blank" aria-label="GitHub"><!--[--><!--]--> GitHub <span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span><!--[--><!--]--></a></div><!--]--></nav><!--[--><!--]--><button class="toggle-color-mode-button" title="toggle color mode"><svg style="" class="icon" focusable="false" viewBox="0 0 32 32"><path d="M16 12.005a4 4 0 1 1-4 4a4.005 4.005 0 0 1 4-4m0-2a6 6 0 1 0 6 6a6 6 0 0 0-6-6z" fill="currentColor"></path><path d="M5.394 6.813l1.414-1.415l3.506 3.506L8.9 10.318z" fill="currentColor"></path><path d="M2 15.005h5v2H2z" fill="currentColor"></path><path d="M5.394 25.197L8.9 21.691l1.414 1.415l-3.506 3.505z" fill="currentColor"></path><path d="M15 25.005h2v5h-2z" fill="currentColor"></path><path d="M21.687 23.106l1.414-1.415l3.506 3.506l-1.414 1.414z" fill="currentColor"></path><path d="M25 15.005h5v2h-5z" fill="currentColor"></path><path d="M21.687 8.904l3.506-3.506l1.414 1.415l-3.506 3.505z" fill="currentColor"></path><path d="M15 2.005h2v5h-2z" fill="currentColor"></path></svg><svg style="display:none;" class="icon" focusable="false" viewBox="0 0 32 32"><path d="M13.502 5.414a15.075 15.075 0 0 0 11.594 18.194a11.113 11.113 0 0 1-7.975 3.39c-.138 0-.278.005-.418 0a11.094 11.094 0 0 1-3.2-21.584M14.98 3a1.002 1.002 0 0 0-.175.016a13.096 13.096 0 0 0 1.825 25.981c.164.006.328 0 .49 0a13.072 13.072 0 0 0 10.703-5.555a1.01 1.01 0 0 0-.783-1.565A13.08 13.08 0 0 1 15.89 4.38A1.015 1.015 0 0 0 14.98 3z" fill="currentColor"></path></svg></button><!----></div></header><!--]--><div class="sidebar-mask"></div><!--[--><aside class="sidebar"><nav class="navbar-items"><!--[--><div class="navbar-item"><a href="/" class="" aria-label="首页"><!--[--><!--]--> 首页 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/menu/" class="" aria-label="目录"><!--[--><!--]--> 目录 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/cafe/" class="" aria-label="Cafe"><!--[--><!--]--> Cafe <!--[--><!--]--></a></div><div class="navbar-item"><a href="/tools/" class="" aria-label="工具"><!--[--><!--]--> 工具 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/link/" class="" aria-label="链接"><!--[--><!--]--> 链接 <!--[--><!--]--></a></div><div class="navbar-item"><a href="/credits/" class="" aria-label="Credits"><!--[--><!--]--> Credits <!--[--><!--]--></a></div><div class="navbar-item"><a class="external-link" href="https://github.com/BBleae/hrt-book" rel="noopener noreferrer" target="_blank" aria-label="GitHub"><!--[--><!--]--> GitHub <span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span><!--[--><!--]--></a></div><!--]--></nav><!--[--><!--]--><ul class="sidebar-items"><!--[--><li><p tabindex="0" class="sidebar-item sidebar-heading collapsible">Part 0 HRT 介绍与基本 <span class="right arrow"></span></p><ul style="display:none;" class="sidebar-item-children"><!--[--><li><a href="/parts/Part0.html#跨性别激素代替疗法-transfem-hrt" class="sidebar-item" aria-label="跨性别激素代替疗法 (Transfem HRT)"><!--[--><!--]--> 跨性别激素代替疗法 (Transfem HRT) <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#性激素-种类、作用" class="sidebar-item" aria-label="性激素: 种类、作用"><!--[--><!--]--> 性激素: 种类、作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#性激素-正常水平" class="sidebar-item" aria-label="性激素: 正常水平"><!--[--><!--]--> 性激素: 正常水平 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#性腺抑制" class="sidebar-item" aria-label="性腺抑制"><!--[--><!--]--> 性腺抑制 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#hrt-效果-生理变化时间线" class="sidebar-item" aria-label="HRT 效果/生理变化时间线"><!--[--><!--]--> HRT 效果/生理变化时间线 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#性激素水平-参考文献" class="sidebar-item" aria-label="性激素水平: 参考文献"><!--[--><!--]--> 性激素水平: 参考文献 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part0.html#雌激素" class="sidebar-item" aria-label="雌激素"><!--[--><!--]--> 雌激素 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#黄体酮" class="sidebar-item" aria-label="黄体酮"><!--[--><!--]--> 黄体酮 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#雄激素" class="sidebar-item" aria-label="雄激素"><!--[--><!--]--> 雄激素 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part0.html#给药途径" class="sidebar-item" aria-label="给药途径"><!--[--><!--]--> 给药途径 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#不推荐使用的-hrt-药物例子" class="sidebar-item" aria-label="不推荐使用的 HRT 药物例子"><!--[--><!--]--> 不推荐使用的 HRT 药物例子 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#概要、重点" class="sidebar-item" aria-label="概要、重点"><!--[--><!--]--> 概要、重点 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part0.html#小常识与道具" class="sidebar-item" aria-label="小常识与道具"><!--[--><!--]--> 小常识与道具 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part0.html#hrt-前血液检查项目-pre-labs" class="sidebar-item" aria-label="HRT 前血液检查项目 (Pre-labs)"><!--[--><!--]--> HRT 前血液检查项目 (Pre-labs) <!--[--><!--]--></a><!----></li><!--]--></ul></li><!--]--></ul></li><li><a href="/parts/Part1.html" class="sidebar-item sidebar-heading" aria-label="Part 1"><!--[--><!--]--> Part 1 <!--[--><!--]--></a><!----></li><li><p tabindex="0" class="sidebar-item sidebar-heading collapsible">Part 2 雌激素 (Estrogens) <span class="right arrow"></span></p><ul style="display:none;" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#种类与介绍" class="router-link-active router-link-exact-active sidebar-item" aria-label="种类与介绍"><!--[--><!--]--> 种类与介绍 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#天然雌激素-bioidentical-estrogens" class="router-link-active router-link-exact-active sidebar-item" aria-label="天然雌激素 (Bioidentical Estrogens)"><!--[--><!--]--> 天然雌激素 (Bioidentical Estrogens) <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#合成雌激素-non-bioidentical-estrogens" class="router-link-active router-link-exact-active sidebar-item" aria-label="合成雌激素 (Non-bioidentical Estrogens)"><!--[--><!--]--> 合成雌激素 (Non-bioidentical Estrogens) <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇-给药途径" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇: 给药途径"><!--[--><!--]--> 雌二醇: 给药途径 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#口服-吞服-、含服" class="router-link-active router-link-exact-active sidebar-item" aria-label="口服 (吞服)、含服"><!--[--><!--]--> 口服 (吞服)、含服 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#透皮给药" class="router-link-active router-link-exact-active sidebar-item" aria-label="透皮给药"><!--[--><!--]--> 透皮给药 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#注射" class="router-link-active router-link-exact-active sidebar-item" aria-label="注射"><!--[--><!--]--> 注射 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇-剂量" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇: 剂量"><!--[--><!--]--> 雌二醇: 剂量 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#雌二醇注射单药治疗-monotherapy-的推荐剂量" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇注射单药治疗 (monotherapy) 的推荐剂量"><!--[--><!--]--> 雌二醇注射单药治疗 (monotherapy) 的推荐剂量 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇酯注射-水平-图表" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇酯注射: 水平 (图表)"><!--[--><!--]--> 雌二醇酯注射: 水平 (图表) <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇-剂量与水平的关系" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇: 剂量与水平的关系"><!--[--><!--]--> 雌二醇: 剂量与水平的关系 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇-口服" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇: 口服"><!--[--><!--]--> 雌二醇: 口服 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#效果、雌酮的作用" class="router-link-active router-link-exact-active sidebar-item" aria-label="效果、雌酮的作用"><!--[--><!--]--> 效果、雌酮的作用 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#风险-雌酮与乳癌、血栓关系" class="router-link-active router-link-exact-active sidebar-item" aria-label="风险: 雌酮与乳癌、血栓关系"><!--[--><!--]--> 风险: 雌酮与乳癌、血栓关系 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇-舌下含服" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇: 舌下含服"><!--[--><!--]--> 雌二醇: 舌下含服 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#备注" class="router-link-active router-link-exact-active sidebar-item" aria-label="备注"><!--[--><!--]--> 备注 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#口服与含服对比-price-et-al-1997" class="router-link-active router-link-exact-active sidebar-item" aria-label="口服与含服对比: Price et al. (1997)"><!--[--><!--]--> 口服与含服对比: Price et al. (1997) <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#雌二醇-透皮给药" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌二醇: 透皮给药"><!--[--><!--]--> 雌二醇: 透皮给药 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#药理" class="router-link-active router-link-exact-active sidebar-item" aria-label="药理"><!--[--><!--]--> 药理 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#功效" class="router-link-active router-link-exact-active sidebar-item" aria-label="功效"><!--[--><!--]--> 功效 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#安全性" class="router-link-active router-link-exact-active sidebar-item" aria-label="安全性"><!--[--><!--]--> 安全性 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#结论" class="router-link-active router-link-exact-active sidebar-item" aria-label="结论"><!--[--><!--]--> 结论 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#雌激素-血栓风险" class="router-link-active router-link-exact-active sidebar-item" aria-label="雌激素: 血栓风险"><!--[--><!--]--> 雌激素: 血栓风险 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a aria-current="page" href="/parts/Part2.html#血栓风险率" class="router-link-active router-link-exact-active sidebar-item" aria-label="血栓风险率"><!--[--><!--]--> 血栓风险率 <!--[--><!--]--></a><!----></li><li><a aria-current="page" href="/parts/Part2.html#其他因素" class="router-link-active router-link-exact-active sidebar-item" aria-label="其他因素"><!--[--><!--]--> 其他因素 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a aria-current="page" href="/parts/Part2.html#非天然雌激素-肝脏代谢抗性" class="router-link-active router-link-exact-active sidebar-item" aria-label="非天然雌激素: 肝脏代谢抗性"><!--[--><!--]--> 非天然雌激素: 肝脏代谢抗性 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><p tabindex="0" class="sidebar-item sidebar-heading collapsible">Part 3 孕激素 (Progestogens) 篇 <span class="right arrow"></span></p><ul style="display:none;" class="sidebar-item-children"><!--[--><li><a href="/parts/Part3.html#孕激素-介绍" class="sidebar-item" aria-label="孕激素: 介绍"><!--[--><!--]--> 孕激素: 介绍 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#孕激素-给药途径" class="sidebar-item" aria-label="孕激素: 给药途径"><!--[--><!--]--> 孕激素: 给药途径 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part3.html#口服" class="sidebar-item" aria-label="口服"><!--[--><!--]--> 口服 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#舌下含服" class="sidebar-item" aria-label="舌下含服"><!--[--><!--]--> 舌下含服 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#直肠给药" class="sidebar-item" aria-label="直肠给药"><!--[--><!--]--> 直肠给药 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#注射" class="sidebar-item" aria-label="注射"><!--[--><!--]--> 注射 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part3.html#孕激素-推荐剂量" class="sidebar-item" aria-label="孕激素: 推荐剂量"><!--[--><!--]--> 孕激素: 推荐剂量 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#口服黄体酮-低水平、极弱的孕激素作用" class="sidebar-item" aria-label="口服黄体酮: 低水平、极弱的孕激素作用"><!--[--><!--]--> 口服黄体酮: 低水平、极弱的孕激素作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#口服黄体酮-作用、影响" class="sidebar-item" aria-label="口服黄体酮: 作用、影响"><!--[--><!--]--> 口服黄体酮: 作用、影响 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#口服黄体酮-生物半衰期、持续时间、利用度" class="sidebar-item" aria-label="口服黄体酮: 生物半衰期、持续时间、利用度"><!--[--><!--]--> 口服黄体酮: 生物半衰期、持续时间、利用度 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#口服黄体酮-高剂量与神经甾体的副作用" class="sidebar-item" aria-label="口服黄体酮: 高剂量与神经甾体的副作用"><!--[--><!--]--> 口服黄体酮: 高剂量与神经甾体的副作用 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part3.html#关于口服黄体酮的代谢产物" class="sidebar-item" aria-label="关于口服黄体酮的代谢产物"><!--[--><!--]--> 关于口服黄体酮的代谢产物 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part3.html#黄体酮-非口服给药途径" class="sidebar-item" aria-label="黄体酮: 非口服给药途径"><!--[--><!--]--> 黄体酮: 非口服给药途径 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#黄体酮-直肠给药途径-by-dr-will-powers" class="sidebar-item" aria-label="黄体酮: 直肠给药途径 by Dr Will Powers"><!--[--><!--]--> 黄体酮: 直肠给药途径 by Dr Will Powers <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#黄体制剂作为-hrt-中的孕激素替代" class="sidebar-item" aria-label="黄体制剂作为 HRT 中的孕激素替代"><!--[--><!--]--> 黄体制剂作为 HRT 中的孕激素替代 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part3.html#泌乳素-prl-监测指南" class="sidebar-item" aria-label="泌乳素 (PRL): 监测指南"><!--[--><!--]--> 泌乳素 (PRL): 监测指南 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><p tabindex="0" class="sidebar-item sidebar-heading collapsible">Part 4 乳房发育 (Breast Development) 篇 <span class="right arrow"></span></p><ul style="display:none;" class="sidebar-item-children"><!--[--><li><a href="/parts/Part4.html#黄体酮在青春期女性乳房发育中的作用" class="sidebar-item" aria-label="黄体酮在青春期女性乳房发育中的作用"><!--[--><!--]--> 黄体酮在青春期女性乳房发育中的作用 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part4.html#关于黄体酮对于啮齿类动物乳腺形成的关系" class="sidebar-item" aria-label="关于黄体酮对于啮齿类动物乳腺形成的关系"><!--[--><!--]--> 关于黄体酮对于啮齿类动物乳腺形成的关系 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part4.html#患有-cais-完全型雄激素不敏感综合征-的女性的乳房发育" class="sidebar-item" aria-label="患有 CAIS (完全型雄激素不敏感综合征) 的女性的乳房发育"><!--[--><!--]--> 患有 CAIS (完全型雄激素不敏感综合征) 的女性的乳房发育 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part4.html#早期导入孕激素造成乳房发育不良的可能性" class="sidebar-item" aria-label="早期导入孕激素造成乳房发育不良的可能性"><!--[--><!--]--> 早期导入孕激素造成乳房发育不良的可能性 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part4.html#cpa-在跨性别女性-hrt-的使用" class="sidebar-item" aria-label="CPA 在跨性别女性 HRT 的使用"><!--[--><!--]--> CPA 在跨性别女性 HRT 的使用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part4.html#关于治疗乳房肥大症-macromastia-的孕激素使用" class="sidebar-item" aria-label="关于治疗乳房肥大症(Macromastia)的孕激素使用"><!--[--><!--]--> 关于治疗乳房肥大症(Macromastia)的孕激素使用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part4.html#_17α-羟化酶-17-20-裂解酶缺乏症-17α-hydroxylase-17-20-lyase-deficiency" class="sidebar-item" aria-label="17α-羟化酶 / 17,20 裂解酶缺乏症 (17α-Hydroxylase/17,20-Lyase Deficiency)"><!--[--><!--]--> 17α-羟化酶 / 17,20 裂解酶缺乏症 (17α-Hydroxylase/17,20-Lyase Deficiency) <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part4.html#产前雄激素的暴露导致跨性别女性乳房发育限制的可能性" class="sidebar-item" aria-label="产前雄激素的暴露导致跨性别女性乳房发育限制的可能性"><!--[--><!--]--> 产前雄激素的暴露导致跨性别女性乳房发育限制的可能性 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part4.html#高剂量雌激素与乳房发育的关系" class="sidebar-item" aria-label="高剂量雌激素与乳房发育的关系"><!--[--><!--]--> 高剂量雌激素与乳房发育的关系 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><p tabindex="0" class="sidebar-item sidebar-heading collapsible">Part 5 双氢睾酮 (DHT) 和 5α-还原酶抑制剂 <span class="right arrow"></span></p><ul style="display:none;" class="sidebar-item-children"><!--[--><li><a href="/parts/Part5.html#_5α-还原酶抑制剂" class="sidebar-item" aria-label="5α-还原酶抑制剂"><!--[--><!--]--> 5α-还原酶抑制剂 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part5.html#价格" class="sidebar-item" aria-label="价格"><!--[--><!--]--> 价格 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part5.html#外国药商一列" class="sidebar-item" aria-label="外国药商一列"><!--[--><!--]--> 外国药商一列 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part5.html#推荐剂量" class="sidebar-item" aria-label="推荐剂量"><!--[--><!--]--> 推荐剂量 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part5.html#dht-的合成途径" class="sidebar-item" aria-label="DHT 的合成途径"><!--[--><!--]--> DHT 的合成途径 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part5.html#dht-异常的例子" class="sidebar-item" aria-label="DHT 异常的例子"><!--[--><!--]--> DHT 异常的例子 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><p tabindex="0" class="sidebar-item sidebar-heading collapsible">Part 6 抗雄激素药物 (Antiandrogens) 篇 <span class="right arrow"></span></p><ul style="display:none;" class="sidebar-item-children"><!--[--><li><a href="/parts/Part6.html#种类" class="sidebar-item" aria-label="种类"><!--[--><!--]--> 种类 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part6.html#大致的排名" class="sidebar-item" aria-label="大致的排名"><!--[--><!--]--> 大致的排名 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part6.html#醋酸环丙孕酮-cpa" class="sidebar-item" aria-label="醋酸环丙孕酮 (CPA)"><!--[--><!--]--> 醋酸环丙孕酮 (CPA) <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part6.html#cpa-介绍" class="sidebar-item" aria-label="CPA: 介绍"><!--[--><!--]--> CPA: 介绍 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-价格" class="sidebar-item" aria-label="CPA: 价格"><!--[--><!--]--> CPA: 价格 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-过量孕激素作用" class="sidebar-item" aria-label="CPA: 过量孕激素作用"><!--[--><!--]--> CPA: 过量孕激素作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-剂量与睾酮抑制能力" class="sidebar-item" aria-label="CPA: 剂量与睾酮抑制能力"><!--[--><!--]--> CPA: 剂量与睾酮抑制能力 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-配合雌激素的睾酮抑制作用" class="sidebar-item" aria-label="CPA: 配合雌激素的睾酮抑制作用"><!--[--><!--]--> CPA: 配合雌激素的睾酮抑制作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-第二抗雄机理" class="sidebar-item" aria-label="CPA : 第二抗雄机理"><!--[--><!--]--> CPA : 第二抗雄机理 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-推荐剂量" class="sidebar-item" aria-label="CPA: 推荐剂量"><!--[--><!--]--> CPA: 推荐剂量 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-主要风险" class="sidebar-item" aria-label="CPA: 主要风险"><!--[--><!--]--> CPA: 主要风险 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-血药浓度" class="sidebar-item" aria-label="CPA: 血药浓度"><!--[--><!--]--> CPA: 血药浓度 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-血液检查项目" class="sidebar-item" aria-label="CPA: 血液检查项目"><!--[--><!--]--> CPA: 血液检查项目 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-药代动力学-pharmacokinetics" class="sidebar-item" aria-label="CPA: 药代动力学 (Pharmacokinetics)"><!--[--><!--]--> CPA: 药代动力学 (Pharmacokinetics) <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-建议" class="sidebar-item" aria-label="CPA: 建议"><!--[--><!--]--> CPA: 建议 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#cpa-结论" class="sidebar-item" aria-label="CPA: 结论"><!--[--><!--]--> CPA: 结论 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part6.html#螺内酯" class="sidebar-item" aria-label="螺内酯"><!--[--><!--]--> 螺内酯 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part6.html#螺内酯-介绍" class="sidebar-item" aria-label="螺内酯: 介绍"><!--[--><!--]--> 螺内酯: 介绍 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-价格" class="sidebar-item" aria-label="螺内酯: 价格"><!--[--><!--]--> 螺内酯: 价格 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-抗雄机理" class="sidebar-item" aria-label="螺内酯: 抗雄机理"><!--[--><!--]--> 螺内酯: 抗雄机理 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-推荐剂量" class="sidebar-item" aria-label="螺内酯: 推荐剂量"><!--[--><!--]--> 螺内酯: 推荐剂量 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-主要副作用" class="sidebar-item" aria-label="螺内酯: 主要副作用"><!--[--><!--]--> 螺内酯: 主要副作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-血液检查项目" class="sidebar-item" aria-label="螺内酯: 血液检查项目"><!--[--><!--]--> 螺内酯: 血液检查项目 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-药代动力学" class="sidebar-item" aria-label="螺内酯: 药代动力学"><!--[--><!--]--> 螺内酯: 药代动力学 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#螺内酯-总结" class="sidebar-item" aria-label="螺内酯: 总结"><!--[--><!--]--> 螺内酯: 总结 <!--[--><!--]--></a><!----></li><!--]--></ul></li><li><a href="/parts/Part6.html#比卡鲁胺" class="sidebar-item" aria-label="比卡鲁胺"><!--[--><!--]--> 比卡鲁胺 <!--[--><!--]--></a><ul style="" class="sidebar-item-children"><!--[--><li><a href="/parts/Part6.html#比卡鲁胺-介绍" class="sidebar-item" aria-label="比卡鲁胺: 介绍"><!--[--><!--]--> 比卡鲁胺: 介绍 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-价格" class="sidebar-item" aria-label="比卡鲁胺: 价格"><!--[--><!--]--> 比卡鲁胺: 价格 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-抗雄机理" class="sidebar-item" aria-label="比卡鲁胺: 抗雄机理"><!--[--><!--]--> 比卡鲁胺: 抗雄机理 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-副作用" class="sidebar-item" aria-label="比卡鲁胺: 副作用"><!--[--><!--]--> 比卡鲁胺: 副作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺单药治疗最大的副作用——乳房发育-gynecomastia" class="sidebar-item" aria-label="比卡鲁胺单药治疗最大的副作用——乳房发育 (Gynecomastia)"><!--[--><!--]--> 比卡鲁胺单药治疗最大的副作用——乳房发育 (Gynecomastia) <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-剂量" class="sidebar-item" aria-label="比卡鲁胺: 剂量"><!--[--><!--]--> 比卡鲁胺: 剂量 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺稳态血药浓度" class="sidebar-item" aria-label="比卡鲁胺稳态血药浓度"><!--[--><!--]--> 比卡鲁胺稳态血药浓度 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-单药治疗的抗雄激素作用" class="sidebar-item" aria-label="比卡鲁胺: 单药治疗的抗雄激素作用"><!--[--><!--]--> 比卡鲁胺: 单药治疗的抗雄激素作用 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-血液检查项目" class="sidebar-item" aria-label="比卡鲁胺: 血液检查项目"><!--[--><!--]--> 比卡鲁胺: 血液检查项目 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-q-a" class="sidebar-item" aria-label="比卡鲁胺 Q&amp;A"><!--[--><!--]--> 比卡鲁胺 Q&amp;A <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#比卡鲁胺-留意事项、结论" class="sidebar-item" aria-label="比卡鲁胺: 留意事项、结论"><!--[--><!--]--> 比卡鲁胺: 留意事项、结论 <!--[--><!--]--></a><!----></li><li><a href="/parts/Part6.html#关于比卡鲁胺作为跨性别女性-hrt-抗雄激素药物——已发布的所有文献-all-published-literature-on-bicalutamide" class="sidebar-item" aria-label="关于比卡鲁胺作为跨性别女性 HRT 抗雄激素药物——已发布的所有文献 All Published Literature on Bicalutamide"><!--[--><!--]--> 关于比卡鲁胺作为跨性别女性 HRT 抗雄激素药物——已发布的所有文献 All Published Literature on Bicalutamide <!--[--><!--]--></a><!----></li><!--]--></ul></li><!--]--></ul></li><li><a href="/parts/Part7.html" class="sidebar-item sidebar-heading" aria-label="Part 7 常用缩写表(WIP)"><!--[--><!--]--> Part 7 常用缩写表(WIP) <!--[--><!--]--></a><!----></li><!--]--></ul><!--[--><!--]--></aside><!--]--><!--[--><main class="page"><!--[--><!--]--><div class="theme-default-content"><!--[--><!--]--><div><h1 id="part-2-雌激素-estrogens" tabindex="-1"><a class="header-anchor" href="#part-2-雌激素-estrogens" aria-hidden="true">#</a> Part 2 雌激素 (Estrogens)</h1><h2 id="种类与介绍" tabindex="-1"><a class="header-anchor" href="#种类与介绍" aria-hidden="true">#</a> 种类与介绍</h2><h3 id="天然雌激素-bioidentical-estrogens" tabindex="-1"><a class="header-anchor" href="#天然雌激素-bioidentical-estrogens" aria-hidden="true">#</a> 天然雌激素 (Bioidentical Estrogens)</h3><ul><li>雌二醇 <ul><li>雌二醇片 (诺坤复)</li><li>雌二醇凝胶</li><li>雌二醇贴片</li></ul></li><li>雌二醇酯 (esters) <ul><li>戊酸雌二醇 (Estradiol Valerate / EV) <ul><li>片剂 (补佳乐)</li><li>油溶剂 (“日雌”)</li></ul></li><li>庚酸雌二醇 (Estradiol Enanthate / EEn)</li><li>环戊丙酸雌二醇 (Estradiol Cypionate / EC)</li><li>苯甲酸雌二醇 (Estradiol Benzoate / EB)</li><li>聚磷酸雌二醇 (Polyestradiol phosphate / PEP)</li></ul></li></ul><p>在跨性别女性中使用的雌二醇有——雌二醇与雌二醇酯 (esters). 雌二醇酯是雌二醇的前体药物 (既，在体内转换成雌二醇)，与雌二醇有着相似的生物活性. 但它们被用于注射时会有更长久的活性，由于在注射部位的吸收较慢. 这使它们能够在给药时间上的频率降低. 聚磷酸雌二醇 (PEP) 是一种以聚合物 (polymer) 形式存在的雌二醇前药. 它的代谢较缓慢，持续时间也很长.</p><h3 id="合成雌激素-non-bioidentical-estrogens" tabindex="-1"><a class="header-anchor" href="#合成雌激素-non-bioidentical-estrogens" aria-hidden="true">#</a> 合成雌激素 (Non-bioidentical Estrogens)</h3><ul><li>炔雌醇 (Ethinylestradiol / EE) <ul><li>避孕药等药物 (如: 优思明、妈富隆、达英 35)</li></ul></li><li>结合雌激素 (Conjugated estrogens / CEEs) <ul><li>绝经期激素治疗药物</li></ul></li><li>己烯雌酚 (Diethylstilbestrol / DES)</li></ul><p>人工合成雌激素，具有肝脏代谢抗性，在对雌激素调节的肝脏合成有不成比例的影响. 而这结果导致它们拥有更大的风险如: 血栓与心血管疾病. 同时因为风险原因以及在跨性别女性中需要使用较高剂量的雌激素来达到有效地睾酮抑制，合成雌激素绝不应该使用于跨性别 HRT 中.</p><p>雌激素可以高剂量单独使用来抑制睾酮至女性范围水平. 而低剂量的雌激素可以与抗雄激素或孕激素联合使用来达到比较接近生理水平的 E2. 这将会导致雌激素部分地抑制睾酮，并通过抗雄激素药物或孕激素来进一步地抑制或拮抗剩余的睾酮. 但是，在 HRT 导入抗雄激素药物或孕激素药物也将增加这些药物带来的副作用与风险.</p><p>低水平的雌激素能带来的女性化作用在雄激素存在的影响下是有限的. 高剂量的雌激素，除了能带来更强力的睾酮抑制能力之外，并不会带来更强的女性化作用. 事实上，有迹象表明高剂量雌激素可能会导致更差的乳房发育. 高剂量雌激素的使用包括雌二醇，也将会提高血栓与心血管疾病的风险 (雌激素——血栓风险篇). 所以使用生理水平剂量的雌激素可能较佳. 但同时，高剂量雌激素在睾酮抑制方面上非常有用，而且非口服雌二醇给药途径所带来的风险较低. 这也特别限于特定高风险人群如: 高龄、缺乏活动、肥胖症、伴随孕激素药物使用、吸烟、手术、易栓症等等. 在健康年轻的人身上，高剂量非口服雌二醇的使用，在一定范围中，是可以接受的.</p><h2 id="雌二醇-给药途径" tabindex="-1"><a class="header-anchor" href="#雌二醇-给药途径" aria-hidden="true">#</a> 雌二醇: 给药途径</h2><h3 id="口服-吞服-、含服" tabindex="-1"><a class="header-anchor" href="#口服-吞服-、含服" aria-hidden="true">#</a> 口服 (吞服)、含服</h3><p>口服雌二醇的形式有雌二醇与戊酸雌二醇 (EV). 雌二醇口服途径存在生物利用度问题，并且常导致低水平的雌二醇浓度，从而可限制其雌激素作用以及导致睾酮抑制不足 (Wiki; Leinung et al., 2018; Leinung, 2014). 口服用的雌二醇片可以用于舌下含服. 雌二醇含服途径拥有比起口服 5 倍更高的生物利用度，这约为 ~25%，相比于口服的 3-5% (Wiki). 但是由于含服雌二醇的持续时间较短，所以建议分次服用来维持较稳定的雌二醇水平. 口服 EV 片也像雌二醇片，可以被用于含服. 颊给药途径 (buccal) 也与舌下含服一样，具有相似的特性，但不常被使用. (详细看——舌下含服篇)</p><h3 id="透皮给药" tabindex="-1"><a class="header-anchor" href="#透皮给药" aria-hidden="true">#</a> 透皮给药</h3><p>雌二醇贴片可以被用于此给药途径，但可能需要 2~4 张贴片来达到足够的雌二醇水平以抑制睾酮 (雌二醇单疗的情况下). 同样的，雌二醇凝胶也能用于此给药途径，但是可能必须使用较多分量的凝胶来达到足够的雌二醇水平. 凝胶可以选择在生殖器上使用，特别是在阴囊或术后阴唇上，在此部位使用凝胶比用于其他部位如手臂、腹部、臀部相比更能达到较高的雌二醇水平. (详细看——透皮给药篇)</p><h3 id="注射" tabindex="-1"><a class="header-anchor" href="#注射" aria-hidden="true">#</a> 注射</h3><p>对于雌二醇酯的注射，可以选择肌肉注射或皮下注射. 皮下注射比较容易实行，更不痛且比肌注更方便，是优选的注射方式. 雌二醇酯注射能达到高水平的雌二醇，并且取决于使用的酯 (ester)，持续时间可长达数天或数周. 一种雌二醇注射——聚磷酸雌二醇 (PEP) 与其他雌二醇酯不同，必须使用肌注，其效用持续时间可长达数月 (半衰期为 70 天). 但是 PEP 大多仅限于北欧地区 (Wiki).</p><p>由于口服雌二醇会导致在肝脏内非常高的雌酮(E1)水平，而且对雌激素调节的肝蛋白合成有着不成比例的影响，虽然非口服途径比较不方便， 但还是优选的.特别是在需要使用更高雌激素剂量来抑制睾酮的情况下，口服途径会提高血栓、心血管疾病等风险.这些风险在选择非口服途径时能大幅地降低.</p><h2 id="雌二醇-剂量" tabindex="-1"><a class="header-anchor" href="#雌二醇-剂量" aria-hidden="true">#</a> 雌二醇: 剂量</h2><table><thead><tr><th>药物</th><th>给药途径</th><th>形式</th><th>剂量</th></tr></thead><tbody><tr><td rowspan="5">雌二醇</td><td>口服</td><td rowspan="2">片剂</td><td>2–8 mg/天</td></tr><tr><td>含服/口颊给药</td><td>0.5–2 mg (1–4 次/天)</td></tr><tr><td rowspan="2">透皮给药</td><td>贴剂</td><td>50–300 μg/天</td></tr><tr><td>凝胶</td><td>2–6 mg/天</td></tr><tr><td>皮下植入</td><td>Pellet</td><td>25–150 mg/6 个月</td></tr><tr><td rowspan="3">戊酸雌二醇 (EV)</td><td>口服</td><td rowspan="2">片剂</td><td>2–10 mg/天</td></tr><tr><td>含服/颊给药</td><td>0.5–2 mg (1–4 次/天)</td></tr><tr><td rowspan="4">肌注/皮下注射</td><td rowspan="4">油溶液</td><td>2–6 mg/周； 1.5–4 mg/5 天； 或 <span class="green">5–7 mg/5 天*</span></td></tr><tr><td>庚酸雌二醇 (EEn)</td><td>4–12 mg/两周；<span class="green">11 mg/周*</span>；或 15mg/10 天</td></tr><tr><td>环戊丙酸雌二醇 (EC)</td><td>2–6 mg/周</td></tr><tr><td>苯甲酸雌二醇 (EB)</td><td>1–3 mg 两次/周</td></tr><tr><td>聚磷酸雌二醇 (PEP)</td><td>肌注</td><td>水溶液</td><td><span class="yellow">40–160 mg/月**</span></td></tr></tbody></table><p class="green">*单药治疗</p><p class="yellow">**PEP 的情况，起初的第一次或两次剂量可以使用 240–320 mg，以更快速地达到稳态血药浓度.</p><p>雌二醇治疗中个体之间能达到的雌二醇水平差异非常大. 也就是说，使用相同剂量下达到的雌二醇水平在每个人之间可能存在着非常大的差异. 这差异在口服与透皮雌二醇途径中最大. 因此，雌二醇的推荐剂量不是绝对的，而应该根据情况以及血液检查来进行个体化. 同时也应注意的是，检测出的雌二醇水平数值在每份报告中存在着差异，特别是含服与注射途径. 但是，这种变化是可以预测，并且可以通过适当的血液检查时机将其最小化的.</p><p>在性腺去除后 (睾丸切除手术或 SRS)，雌激素剂量可以降低或调整至女性生物水平范围. 绝经前女性的平均雌二醇分泌水平在一个月经周期内为约 6 mg (<a href="https://scholar.google.com/scholar?cluster=9979206541205334235" target="_blank" rel="noopener noreferrer">Rosenfield et al., 2008<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><h3 id="雌二醇注射单药治疗-monotherapy-的推荐剂量" tabindex="-1"><a class="header-anchor" href="#雌二醇注射单药治疗-monotherapy-的推荐剂量" aria-hidden="true">#</a> 雌二醇注射单药治疗 (monotherapy) 的推荐剂量</h3><h4 id="ev-注射剂量-5–7-mg-5-天" tabindex="-1"><a class="header-anchor" href="#ev-注射剂量-5–7-mg-5-天" aria-hidden="true">#</a> EV 注射剂量: 5–7 mg/5 天</h4><p>最佳的注射剂量是把剂量调低，但是把注射周期调整为其半衰期 (5 天). 这可以避免高剂量 EV 所导致在注射后的 1~2 天内产生非常高的峰值水平. 用于绝经后女性的标准治疗剂量 (10 mg/7 天) 不适合用于跨性别女性中，这剂量会导致注射后 1~2 天内非常高的 E2 水平峰值. 符合其半衰期的 5–7 mg/5 天的剂量可以避免身体经历巨大的峰值与非常低的谷浓度带来的影响. 大幅变化的 E2 水平可能会产生情绪影响等生理现象.</p><h4 id="een-注射剂量-11-mg-周-7-天" tabindex="-1"><a class="header-anchor" href="#een-注射剂量-11-mg-周-7-天" aria-hidden="true">#</a> EEn 注射剂量: 11 mg/周 (7 天)</h4><p>每周 11 mg 的 EEn 剂量平均所能产生的 E2 水平为平均 300–400 pg/mL. 这剂量所能产生的 E2 水平能有效地把睾酮抑制至 &lt;50 ng/dL 以下，而这注射周期也符合 EEn 半衰期的 ~7 天.</p><h2 id="雌二醇酯注射-水平-图表" tabindex="-1"><a class="header-anchor" href="#雌二醇酯注射-水平-图表" aria-hidden="true">#</a> 雌二醇酯注射: 水平 (图表)</h2><p><img src="/assets/Idealized_curves_of_estradiol_levels_after_injection_of_different_estradiol_esters_in_women-c5038d96.png" alt="Idealized_curves_of_estradiol_levels_after_injection_of_different_estradiol_esters_in_women" class="medium-zoom-image"></p><p>Graph: Simplified curves of estradiol levels after intramuscular injection of different estradiol esters in oil solution in women. (<a href="https://www.google.com/url?q=https://doi.org/10.1016%252F0010-7824%252894%252990032-9&amp;sa=D&amp;source=editors&amp;ust=1650986830854456&amp;usg=AOvVaw1Bg5kYMpCWOXGC2k2JO0to" target="_blank" rel="noopener noreferrer">Garza-Flores, 1994<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>)</p><p><span style="color:#dd2a91;">Estradiol benzoate (EB)</span>: 苯甲酸雌二醇</p><p><span style="color:#b14dec;">Estradiol valerate (EV)</span>: 戊酸雌二醇</p><p><span style="color:#7675ed;">Estradiol cypionate (EC)</span>: 环戊丙酸雌二醇</p><p><span style="color:#2e8ebf;">Estradiol enanthate (EEn)</span>: 庚酸雌二醇</p><p>*此图表的曲线是拟合的且检测间隔较长，所以实际情况可能会与其有较大偏差</p><h2 id="雌二醇-剂量与水平的关系" tabindex="-1"><a class="header-anchor" href="#雌二醇-剂量与水平的关系" aria-hidden="true">#</a> 雌二醇: 剂量与水平的关系</h2><table><thead><tr><th style="text-align:center;">给药途径</th><th style="text-align:center;">低剂量</th><th style="text-align:center;">中剂量</th><th style="text-align:center;">高剂量</th><th style="text-align:center;">超高剂量</th></tr></thead><tbody><tr><td style="text-align:center;">口服 (A)</td><td style="text-align:center;">2 mg/天</td><td style="text-align:center;">4 mg/天</td><td style="text-align:center;">8 mg/天</td><td style="text-align:center;">12 mg/天</td></tr><tr><td style="text-align:center;">含服/口颊给药 (B)</td><td style="text-align:center;">0.5–1 mg/天</td><td style="text-align:center;">1–2 mg/天</td><td style="text-align:center;">2–4 mg/天</td><td style="text-align:center;">3–6 mg/天</td></tr><tr><td style="text-align:center;">透皮贴片</td><td style="text-align:center;">50 μg/天</td><td style="text-align:center;">100 μg/天</td><td style="text-align:center;">200 μg/天</td><td style="text-align:center;">300 μg/天</td></tr><tr><td style="text-align:center;">透皮凝胶</td><td style="text-align:center;">1.5 mg/天</td><td style="text-align:center;">3 mg/天</td><td style="text-align:center;">6 mg/天</td><td style="text-align:center;">9 mg/天</td></tr><tr><td style="text-align:center;">肌注/皮下注射</td><td style="text-align:center;">1 mg/周</td><td style="text-align:center;">2 mg/周</td><td style="text-align:center;">4 mg/周</td><td style="text-align:center;">6 mg/周</td></tr><tr><td style="text-align:center;">皮下植入</td><td style="text-align:center;">25 mg/6 个月</td><td style="text-align:center;">50 mg/6 个月</td><td style="text-align:center;">100 mg/6 个月</td><td style="text-align:center;">150 mg/6 个月</td></tr><tr><td style="text-align:center;">平均雌二醇(E2)水平</td><td style="text-align:center;">50 pg/mL (184 pmol/L)</td><td style="text-align:center;">100 pg/mL (367 pmol/L)</td><td style="text-align:center;">200 pg/ml (734 pmol/L)</td><td style="text-align:center;">300 pg/mL (1101 pmol/L)</td></tr><tr><td style="text-align:center;">相等月经周期</td><td style="text-align:center;">卵泡期</td><td style="text-align:center;">全周期</td><td style="text-align:center;">黄体期</td><td style="text-align:center;">排卵期</td></tr></tbody></table><p>A. 口服雌二醇 1.5 mg = 口服雌二醇酯 2 mg.</p><p>B. 含服雌二醇拥有比口服高 ~2–5 倍的生物利用度.</p><p>C. 如果用于生殖器上，可以使用更低剂量的透皮雌二醇.</p><p>D. 肌注或皮下注射: 一周的雌二醇酯总剂量 (EV/EEn/EC/EB). 这些酯之间的分子量差异非常小所以可忽略不计 (<a href="https://en.wikipedia.org/wiki/Template:Structural_properties_of_selected_estradiol_esters" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 最佳注射间隔取决于所用的雌二醇酯的半衰期.</p><p>★ 这些剂量不是绝对性的，所以只应该作为一个非常粗略的参考. 这些数据基于不同研究的广义模型，且具有非常大的个体差异.</p><p>★ 这些剂量只是一般估计的等效剂量，不是典型或推荐的临床剂量.</p><p>请注意: 雌二醇剂量能达到的雌二醇水平存在着非常大的个体差异 (剂量导致的水平因人而异). 同时也该注意的是，某些给药途径存在着较大的时间依赖性的水平波动，主要是含服/口颊给药、肌注/皮下注射 (<a href="https://en.wikipedia.org/wiki/Template:Hormone_levels_with_sublingual_estradiol" target="_blank" rel="noopener noreferrer">Wiki-Graphs<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://commons.wikimedia.org/wiki/File:Estradiol_levels_during_therapy_with_0.25_mg_buccal_estradiol_in_postmenopausal_women.png" target="_blank" rel="noopener noreferrer">Wiki-Graphs<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Hormone_levels_with_estradiol_esters_by_intramuscular_injection" target="_blank" rel="noopener noreferrer">Wiki-Graphs<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><p>对于还没经历或不打算进行性腺切除手术的跨性别女性，可以使用较高剂量的雌二醇来达到强力的睾酮抑制. 平均上，高剂量雌二醇的使用会抑制 90% 的睾酮水平 (至约 50 ng/dL). 所以“高剂量”与“超高剂量”的使用通常用于雌二醇单疗 (不使用抗雄激素药物，而只是使用雌二醇).</p><p>Sources: <a href="https://doi.org/10.1007/978-3-030-14358-9_10" target="_blank" rel="noopener noreferrer">Kuhl (2005); Bruni, V., &amp; Pampaloni, F. (2019)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></p><h2 id="雌二醇-口服" tabindex="-1"><a class="header-anchor" href="#雌二醇-口服" aria-hidden="true">#</a> 雌二醇: 口服</h2><h3 id="效果、雌酮的作用" tabindex="-1"><a class="header-anchor" href="#效果、雌酮的作用" aria-hidden="true">#</a> 效果、雌酮的作用</h3><blockquote><p><strong>错误的说法 (源自于美国医生”Dr Will Powers”)</strong> : 口服雌二醇由于会被肝脏灭活而代谢掉，转化成大量的雌酮(E1).E1 只有 4%的雌激素效果 (与 E2 相比) .这会让体内充满雌酮，而雌酮会与雌二醇(E2)竞争雌激素受体(ERs)，导致受体结合处的雌激素大部分是 E1 而不是 E2，造成“E1 拮抗了 E2，导致女性化作用弱”.</p></blockquote><p>雌酮，根据一项研究显示拥有约 4%的人体 ERs 亲和度 (<a href="https://doi.org/10.1016/j.bcp.2006.02.002" target="_blank" rel="noopener noreferrer">Escande et al., 2006<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).但许多使用人类蛋白质的研究 (包括 Escande et al., 2006) 表明了尽管其低的 ERs 亲和度，雌酮(E1)与雌三醇(E3)都是完全或接近完全的 ERs 激动剂，有能力诱导出与雌二醇相等的反应 (<a href="https://docdro.id/ouFP6PS" target="_blank" rel="noopener noreferrer">Kloosterboer, Schoonen, &amp; Verheul, 2008<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/j.jsbmb.2017.07.022" target="_blank" rel="noopener noreferrer">Perkins, Louw-du Toit, &amp; Africander, 2017<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1530/JME-18-0094" target="_blank" rel="noopener noreferrer">Perkins, Louw-du Toit, &amp; Africander, 2018<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).因此，雌酮可能不存在任何有意义的雌二醇拮抗能力.</p><p>有些跨性别女性声称口服雌二醇给她们带来的女性化效果较差，而雌酮的拮抗力是造成这现象的原因.这其实可能是因为口服雌二醇比非口服造成的雌酮浓度较高.虽然不太可能发生雌酮拮抗，单纯的雌二醇在肝脏内被灭活且大量地转化为雌酮，从而导致雌二醇水平降低，是可以解释在一些跨性别女性睾酮抑制的不足、女性化效果差、以及乳房发育不良等结果的.</p><h3 id="风险-雌酮与乳癌、血栓关系" tabindex="-1"><a class="header-anchor" href="#风险-雌酮与乳癌、血栓关系" aria-hidden="true">#</a> 风险: 雌酮与乳癌、血栓关系</h3><blockquote><p>错误的认识: 口服雌二醇造成的过量雌酮(E1)是导致乳癌与血栓的罪魁祸首.</p></blockquote><p>根据研究，雌二醇、雌酮(E1)、硫酸雌酮(E1S)的循环浓度都与乳癌风险密切相关 (<a href="https://doi.org/10.1080/10408363.2016.1252310" target="_blank" rel="noopener noreferrer">Rezvanpour &amp; Don-Wauchope, 2017<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).雌二醇被认为是导致增加乳癌风险的最终原因，E1 与 E1S 仅是用来测量雌激素活性的间接物.这是因为雌二醇是个强力的 ER 激动剂，而 E1 与 E1S 本身作为 ER 激动剂的效力是非常低的 (也就是说，需要更高的浓度才能够达到与 E2 相同的效果)，并且其活性主要来自于 E2 → E1 的转化.此外，E2 被代谢成 E1 与</p><p>E1S，因此乳癌风险不仅与 E2 水平有关，也与其代谢物有关.有非常少的证据特别表明 E1 和 E1S 比雌二醇(E2)更能导致乳癌.大型 RCTs 使用 SERMs 表明了绝经后女性的乳癌风险强烈依赖于 ER 的激活 (<a href="https://doi.org/10.1007/s00280-016-2959-0" target="_blank" rel="noopener noreferrer">Li et al., 2016<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).大型观察性研究显示口服与透皮雌二醇在乳癌风险上没有任何差异 (<a href="https://doi.org/10.1016/S0140-6736(19)31709-X" target="_blank" rel="noopener noreferrer">CGHFBC, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Worldwide_epidemiological_evidence_on_breast_cancer_risk_with_menopausal_hormone_therapy" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><h2 id="雌二醇-舌下含服" tabindex="-1"><a class="header-anchor" href="#雌二醇-舌下含服" aria-hidden="true">#</a> 雌二醇: 舌下含服</h2><p>由于跨性别者之间对于口服与含服的差别有些许困惑，这篇将会粗略地讲解下这背后的原理.</p><p>当微粉化雌二醇 (micronized estradiol) 被用于口服 (吞服) 时，它的生物利用度最大为 ~5%. 简单地来说，95%其实都会被浪费掉. 而舌下含服的生物利用度为最大~25%，是口服的 5 倍. 这是主要因为如果当雌二醇用于口服时，一部分在体内会被胃酸破坏，而剩下的则被肝脏代谢掉 (Kuhl, Zhang). 肝脏将会把有效的雌二醇转化成效力较低的雌酮 (Estrone; E1) 与硫酸雌酮 (Estrone sulfate; E1S)，这在长期的使用下也会加重对肝脏的负担. 但如果把雌二醇作为含服来使用，口腔粘膜能将一定分量的雌二醇直接吸收到血液中，这能大量的避免经过肝脏代谢，从而导致更高的利用度 (Zhang). 虽然最终肝脏也会代谢掉大量的雌二醇，但这比口服的时候被肝代谢的分量较少. 虽然口内唾液也会破坏掉一部分的雌二醇，但这也比胃酸能破坏掉的雌二醇少(Kuhl).</p><p>另外一点关于口服雌二醇的是: 当雌二醇作为口服使用时，肝脏把有效的雌二醇 (E2) 转化成雌酮 (E1)，而这 E1:E2 的比例一般为 5:1 (Kuhl, 2005)，但也发现可高达 10:1、20:1 (<a href="https://pubmed.ncbi.nlm.nih.gov/8240460/" target="_blank" rel="noopener noreferrer">Kuhnz, Gansau, &amp; Mahler, 1993<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>)，也可能高达 30:1.</p><p>雌酮是种非常低效力的雌激素. 同时雌酮在硫酸雌酮 (E1S) 形态时除了拥有比雌二醇较长的半衰期以及可以转化成雌二醇之外，它在体内真正的作用还未被完全了解.</p><p><img src="/assets/Estradiol_Dose_Comparison-4d357156.jpg" alt="Estradiol_Dose_Comparison" class="medium-zoom-image"></p><p>Graph A: 含服 6 mg 剂量一次服用 vs 含服 6 mg 剂量分次服用(2 mg x3 次)</p><p><strong>剂量服用</strong>: 含服雌二醇时最理想的方式是分次服用. 这是因为含服时会导致庞大的峰值与低谷，并不像口服雌二醇一样能保持较稳定的水平. 含服导致的雌二醇水平在片剂完全融化后 5 分钟内开始迅速上升，30–60 分钟后达峰值浓度，可达的峰值浓度水平是口服的 10 倍高. 这雌二醇水平在 4 小时后开始急速下降，而含服雌二醇的半衰期为 ~8 小时起.</p><p>基于 (Price, 1997) 这项研究，我们可以参考这图表 (Graph A) 来评估含服一次性服用与分次服用的差别.</p><p>这图表显示了一次性服用 6 mg 剂量会达到非常高的峰值水平. 但是，许多研究已经证明了人体不能处理超过 800–1000 pg/mL 的雌二醇，所以超过该极限的雌二醇基本上都只流淌在血液中不带来任何好处，完全被浪费掉.</p><p>Sources: <a href="https://www.google.com/url?q=https://doi.org/10.1080/13697130500148875&amp;sa=D&amp;source=editors&amp;ust=1650986839563747&amp;usg=AOvVaw2gNWQ_c0Qtc8sZaUBvkI4l" target="_blank" rel="noopener noreferrer">Kuhl (2005)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://www.google.com/url?q=https://doi.org/10.1016/S0029-7844(96)00513-3&amp;sa=D&amp;source=editors&amp;ust=1650986839566344&amp;usg=AOvVaw0yHpeGDQI4uzSlqgurFiA5" target="_blank" rel="noopener noreferrer">Price et al. (1997)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://www.google.com/url?q=https://doi.org/10.2165/00003088-200241090-00003&amp;sa=D&amp;source=editors&amp;ust=1650986839566803&amp;usg=AOvVaw2fWgPgXzzZUpwqcvIrsLGn" target="_blank" rel="noopener noreferrer">Zhang et al. (2002)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></p><h3 id="备注" tabindex="-1"><a class="header-anchor" href="#备注" aria-hidden="true">#</a> 备注</h3><p>有时候听见一些乱传闻的跨性别女性说戊酸雌二醇 (EV) 片不能含服，这不正确. 这篇将格外为困惑的姐妹们说明.</p><p>右图为分别 Serhal &amp; Craft 的研究. 此研究使用了戊酸雌二醇 (EV) 片: 补佳乐 (Progynova)，绝经前女性含服 3–4 次/天剂量.</p><ul><li><a href="https://doi.org/10.1016/S0140-6736(89)92762-1" target="_blank" rel="noopener noreferrer">Serhal, P., &amp; Craft, I. (1989). Oocyte donation in 61 patients. The Lancet, 333(8648), 1185–1187.<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li><li><a href="https://doi.org/10.1093/oxfordjournals.bmb.a072432" target="_blank" rel="noopener noreferrer">Serhal, P. (1990). Oocyte donation and surrogacy. British Medical Bulletin, 46(3), 796–812.<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul><p><img src="/assets/sublingual-ev-f3d03fc7.png" alt="sublingual-ev" class="medium-zoom-image"></p><p>这研究显示了 EV (补佳乐) 被良好地吸收并且与含服雌二醇一样达到了相似的雌二醇水平.</p><p>另外值得注意的文献摘录: <a href="https://doi.org/10.5468/ogs.2019.62.1.46" target="_blank" rel="noopener noreferrer">Lim et al. (2019)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></p><p>全部口服雌二醇片都是经过微粉化过的，而 Serhal &amp; Craft 研究中使用的口服戊酸雌二醇 (EV) 也是如此. 微粉化 (micronization) 被认为是对于舌下含服途径的吸收上非常重要的处理 (<a href="https://www.pharmtech.com/view/considerations-developing-sublingual-tablets-overview" target="_blank" rel="noopener noreferrer">Sayeed &amp; Ashraf, 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a> ).</p><p>似乎补佳乐(Progynova)，或可能全部口服 EV 片都是与口服雌二醇片一样，都是被微粉化过的 (<a href="https://doi.org/10.1093/humupd/4.6.856" target="_blank" rel="noopener noreferrer">Devroey &amp; Pados, 1998<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><p>然而可能要注意的是，口服雌二醇、EV 片一般上是被作为口服药物而制造的，不是专门用于舌下含服途径的. 虽然许多此类片剂显然可以通过舌下含服途径被很好地吸收，但是这些片剂可能会在外层上有差异: 糖衣或薄膜衣 (sugar-coated or film-coated)，而这可能会影响片剂溶解时间. 这似乎对 EV 片的生物利用度没有不利影响，但应牢记不同品牌的雌二醇/EV 片在含服使用时可能会在溶解度中有所不同.</p><h3 id="口服与含服对比-price-et-al-1997" tabindex="-1"><a class="header-anchor" href="#口服与含服对比-price-et-al-1997" aria-hidden="true">#</a> 口服与含服对比: <a href="https://doi.org/10.1016/S0029-7844(96)00513-3" target="_blank" rel="noopener noreferrer">Price et al. (1997)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></h3><p><img src="/assets/Price_Estradiol-d183b625.jpg" alt="Price_Estradiol" class="medium-zoom-image"></p><p>SL = 含服</p><p>PO = 口服</p><p>此图表显示主要 1 mg 雌二醇含服与口服在女性体内 24 小时的雌二醇水平.</p><p>含服导致非常高的尖峰水平，而口服导致的雌二醇水平非常低但是较稳定. 同时也需注意，含服导致的峰值不但更高，其导致的平均雌二醇水平值也比口服更高. 这显示了口服雌二醇大幅劣于含服.</p><h2 id="雌二醇-透皮给药" tabindex="-1"><a class="header-anchor" href="#雌二醇-透皮给药" aria-hidden="true">#</a> 雌二醇: 透皮给药</h2><p>透皮途径是一种被广泛使用的雌二醇给药途径，现有的研究显示透皮雌二醇在女性化效果上与口服雌二醇相比没有任何差异. 虽然两种途径都可以被使用，但口服导致的代谢问题是非生理性的，也同时与血栓、心血管疾病有着很大的关联. 而低量的透皮雌二醇使用不存在这种风险，是比口服雌二醇更优势的给药途径.</p><h3 id="药理" tabindex="-1"><a class="header-anchor" href="#药理" aria-hidden="true">#</a> 药理</h3><p>雌二醇贴剂的话必须持续贴在皮肤上，一般上一周两个贴剂、或一周一次. 雌二醇贴片 50 μg/天的剂量被认为具有与口服雌二醇的 1–2 mg/天剂量、或 1.5 mg/天的凝胶剂量具有同等效力(<a href="https://doi.org/10.1080/13697130500148875" target="_blank" rel="noopener noreferrer">Kuhl, 2005<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/S0378-5122(99)00021-3" target="_blank" rel="noopener noreferrer">Järvinen, Nykänen &amp; Paasiniemi, 1999<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 但是这存在着非常大的个体差异，所以这剂量不是通用剂量.</p><p>雌二醇在女性体内是从卵巢分泌到循环系统的，所以肝脏不会暴露在过量激素的影响下 (<a href="https://doi.org/10.1530/EJE-17-0430" target="_blank" rel="noopener noreferrer">Gravholt et al., 2017<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 透皮雌二醇能有效地模仿这行为. 而口服雌二醇由于会通过胃肠道，与雌激素的过量暴露有关 (<a href="https://doi.org/10.5114/pm.2014.46468" target="_blank" rel="noopener noreferrer">Bińkowska, 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 这行为导致口服与透皮雌二醇存在着许多差异.</p><p>口服雌二醇的 95%被代谢成为雌酮以及其他微弱的雌激素 (<a href="https://doi.org/10.1007/978-3-642-60107-1_15" target="_blank" rel="noopener noreferrer">Kuhz, Blode &amp; Zimmermann, 1993<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a> ). 雌酮(E1)与雌二醇(E2)在成人女性、青春期女性中是 1:1 比例，这与透皮雌二醇途径带来的比例相似 (Kuhl, 2005; <a href="https://doi.org/10.1210/clinem/dgz196" target="_blank" rel="noopener noreferrer">Frederiksen et al., 2020<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 而一份口服雌二醇剂量在绝经后女性中发现雌酮的浓度为比雌二醇高 5 倍 (Kuhl, 2005). 在某些患者中，雌酮的浓度可高达 20 倍.由于这原因，口服雌二醇的代谢被认为是非生理性的(<a href="https://doi.org/10.1530/EJE-17-0430" target="_blank" rel="noopener noreferrer">Gravholt et al., 2017<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1111/cen.13869" target="_blank" rel="noopener noreferrer">Mauras et al., 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><h3 id="功效" tabindex="-1"><a class="header-anchor" href="#功效" aria-hidden="true">#</a> 功效</h3><p>在跨性别者之间最常讨论的话题“哪个 HRT 方式最有效助于乳房发育？”. 迄今为止，不存在可以评估乳房发育效果的随机对照试验 (<a href="https://doi.org/10.4158/EP-2019-0183" target="_blank" rel="noopener noreferrer">Reisman, Goldstein &amp; Safer, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1177%2F2042018819871166" target="_blank" rel="noopener noreferrer">Iwamoto et al., 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 同时在科学界内也没有被普遍认可的乳房发育衡量指标.</p><p>但尽管如此，许多观察性研究已经研究过并量化了通过雌激素治疗导致的女性化: (<a href="https://doi.org/10.1111/jsm.12571" target="_blank" rel="noopener noreferrer">Wierckx et al., 2014; de Blok et al., 2018<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 虽然乳房发育没被衡量，但一项回顾性研究发现在不同雌激素使用者之间的丰胸需求率没有统计性差异 (<a href="https://doi.org/10.1210/jc.2012-2030" target="_blank" rel="noopener noreferrer">Seal et al., 2012<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 这表明口服雌二醇 (EV)可能与其他的雌激素 (口服结合雌激素、口服炔雌醇) 没有功效差异.</p><p>最后，在一项针对跨性别女性的大型研究发现，女性型脂肪与男性型脂肪在口服与透皮雌二醇之间不存在统计性差异 (<a href="https://doi.org/10.1530/EJE-17-0496" target="_blank" rel="noopener noreferrer">Klaver et al., 2018<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a> ).</p><p>结论，目前所有临床研究表明雌二醇给药途径之间没有可测量的差异. 综合起来，这些研究表明了乳房发育或女性化与雌激素的给药途径无关.</p><h3 id="安全性" tabindex="-1"><a class="header-anchor" href="#安全性" aria-hidden="true">#</a> 安全性</h3><p>一项关键的研究发现低剂量的口服雌二醇 (2 mg/天或更低) 对静脉血栓栓塞发生率有着轻微但值得重视的负面影响，而低剂量透皮雌二醇 (100 μg/天或更低) 则不会导致此风险的上升 (<a href="https://doi.org/10.1159/000360554" target="_blank" rel="noopener noreferrer">Scarabin, 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>). 因此，透皮雌二醇与口服雌二醇相比，在此风险上有极大优势 (<a href="https://doi.org/10.1080/17425247.2020.1700949" target="_blank" rel="noopener noreferrer">Files &amp; Kling, 2020)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>.</p><h3 id="结论" tabindex="-1"><a class="header-anchor" href="#结论" aria-hidden="true">#</a> 结论</h3><p>口服与透皮雌二醇在代谢上有差异. 口服雌二醇在进入循环系统之前，大量都会被肝脏代谢转化为雌酮和其他雌激素代谢物. 而相反的，透皮雌二醇能避免肝脏的代谢，从而避免雌二醇转化为低效力的雌激素代谢物.</p><p>同时，没有研究表明口服雌二醇与透皮雌二醇在女性化效果中有任何差异. 反而现有的研究显示乳房发育、脂肪分配等女性化效果与雌二醇摄取途径没有任何关系. 因此，透皮雌二醇在生理性剂量上可比口服雌二醇在长期使用中更安全. Additional: Cirrincione et al. (2021)</p><p>Additional: <a href="https://doi.org/10.1089/lgbt.2020.0249" target="_blank" rel="noopener noreferrer">Cirrincione et al. (2021)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></p><h2 id="雌激素-血栓风险" tabindex="-1"><a class="header-anchor" href="#雌激素-血栓风险" aria-hidden="true">#</a> 雌激素: 血栓风险</h2><p>各种雌激素被用于医学中.这包括天然雌激素——雌二醇(E2)，以及非天然雌激素——结合雌激素 (CEEs; Premarin)、炔雌醇(EE)、己烯雌酚(DES).雌二醇(E2)是人体中主要的天然雌激素.CEEs 虽然使用雌二醇作为主要成分，但也含大量从马尿提炼出来的雌激素如马烯雌(7-dehydroestrone)与 17β-二氢马烯雌酮(7-dehydroestradiol).EE、DES 属于由人类制造出来的合成雌激素.DES 在几十年前已经被禁用.雌二醇(E2)被作为口服与非口服途径使用，而非天然雌激素通常被作为口服来使用.右表显示各种雌激素剂量所带来的同等雌二醇水平.</p><table><thead><tr><th style="text-align:center;">雌激素类/途径</th><th style="text-align:center;">超低剂量</th><th style="text-align:center;">低剂量</th><th style="text-align:center;">中剂量</th><th style="text-align:center;">高剂量</th></tr></thead><tbody><tr><td style="text-align:center;">口服 E2</td><td style="text-align:center;">1 mg/天</td><td style="text-align:center;">2 mg/天</td><td style="text-align:center;">4 mg/天</td><td style="text-align:center;">8 mg/天</td></tr><tr><td style="text-align:center;">透皮 E2</td><td style="text-align:center;">25 μg/天</td><td style="text-align:center;">50 μg/天</td><td style="text-align:center;">100 μg/天</td><td style="text-align:center;">200 μg/天</td></tr><tr><td style="text-align:center;">口服 CEEs</td><td style="text-align:center;">0.625 mg/天</td><td style="text-align:center;">1.25 mg/天</td><td style="text-align:center;">2.5 mg/天</td><td style="text-align:center;">5 mg/天</td></tr><tr><td style="text-align:center;">口服 EE</td><td style="text-align:center;">7.5 μg/天</td><td style="text-align:center;">15 μg/天</td><td style="text-align:center;">30μg/天</td><td style="text-align:center;">60 μg/天</td></tr><tr><td style="text-align:center;">口服 DES</td><td style="text-align:center;">0.375 mg/天</td><td style="text-align:center;">0.75 mg/天</td><td style="text-align:center;">1.5 mg/天</td><td style="text-align:center;">3 mg/天</td></tr><tr><td style="text-align:center;">E2 水平</td><td style="text-align:center;">~25 pg/mL</td><td style="text-align:center;">~50 pg/mL</td><td style="text-align:center;">~100 pg/mL</td><td style="text-align:center;">~200 pg/mL</td></tr></tbody></table><p>在一项妇女健康倡议(WHI)的 RCTs 中，低剂量 CEEs 本身(0.625 mg/天)稍微提高了血栓风险，这风险在伴随醋酸甲羟孕酮的使用中大量增高 (<a href="https://en.wikipedia.org/wiki/Template:Results_of_the_Women's_Health_Initiative_menopausal_hormone_therapy_randomized_controlled_trials" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).大型观察性研究发现低剂量口服雌二醇的使用(≤2 mg/天)与血栓风险有关 (<a href="https://doi.org/10.1136/bmj.k4810" target="_blank" rel="noopener noreferrer">Vinogradova et al., 2019a<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://www.sciencedirect.com/science/article/pii/B9780323462020000315" target="_blank" rel="noopener noreferrer">Konkle &amp; Sood, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Risk_of_venous_thromboembolism_with_hormone_therapy_and_birth_control_pills_(QResearch/CPRD)" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).在此风险上口服雌二醇似乎比口服 CEEs 低 (<a href="https://doi.org/10.1001/jamainternmed.2013.11074" target="_blank" rel="noopener noreferrer">Smith et al., 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).与口服雌激素相反地，透皮雌二醇在低/中剂量 (50–100 μg/天)并未提高血栓或心血管风险 (<a href="https://doi.org/10.1210/jc.2015-2237" target="_blank" rel="noopener noreferrer">Mohammed et al., 2015<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; Konkle &amp; Sood, 2019; Vinogradova, Coupland, &amp; Hippisley-Cox, <a href="https://doi.org/10.1016/j.thromres.2020.05.008" target="_blank" rel="noopener noreferrer">2019a; Abou-Ismail, Sridhar, &amp; Nayak, 2020<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><p>使用口服雌二醇(4–8 mg/天剂量)配合抗雄激素药物和/或孕激素药物的跨性别 HRT 疗法已经被有限地评估，在这些研究内显示与低剂量口服雌二醇相比，这些血栓风险大幅增加 (<a href="https://doi.org/10.1530/EJE-13-0493" target="_blank" rel="noopener noreferrer">Wierckx et al., 2013<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/j.jcte.2015.02.003" target="_blank" rel="noopener noreferrer">Weinand &amp; Safer, 2015<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/j.jsxm.2016.09.001" target="_blank" rel="noopener noreferrer">Arnold et al., 2016<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.7326/M17-2785" target="_blank" rel="noopener noreferrer">Getahun et al., 2018<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1007/s11154-018-9454-3" target="_blank" rel="noopener noreferrer">Irwig, 2018<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1161/HYPERTENSIONAHA.119.13080" target="_blank" rel="noopener noreferrer">Connelly et al., 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1111/jth.14626" target="_blank" rel="noopener noreferrer">Connors &amp; Middeldorp, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.2147%2FJBM.S166780" target="_blank" rel="noopener noreferrer">Goldstein et al., 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a> ; <a href="https://doi.org/10.1177%2F2042018819871166" target="_blank" rel="noopener noreferrer">Iwamoto et al., 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1373/clinchem.2018.288316" target="_blank" rel="noopener noreferrer">Khan et al., 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://www.sciencedirect.com/science/article/pii/B9780323462020000315" target="_blank" rel="noopener noreferrer">Konkle &amp; Sood, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1136/bmj.l600" target="_blank" rel="noopener noreferrer">Quinton, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.3389/fendo.2019.00685" target="_blank" rel="noopener noreferrer">Swee, Javaid, &amp; Quinton, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/j.thromres.2020.05.008" target="_blank" rel="noopener noreferrer">Abou-Ismail, Sridhar, &amp; Nayak, 2020<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>)</p><p>现代含有 EE 中等剂量(20–35 μg/天)与生理性剂量孕激素的避孕药会提高血栓风险.另外，它们也提高心脏病与中风的风险至 1.5–2 倍 (<a href="https://doi.org/10.1517/14740338.2014.950654" target="_blank" rel="noopener noreferrer">Lidegaard, 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; Konkle &amp; Sood, 2019).但是， 这并没有提高整体的死亡率，至少在使用避孕药的年轻女性中 (<a href="https://doi.org/10.1136/bmj.c927" target="_blank" rel="noopener noreferrer">Hannaford et al., 2010<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).EE 与雌二醇不同，给药途径似乎不会影响血栓风险.</p><p>短效的雌二醇酯注射如戊酸雌二醇(EV)、环戊丙酸雌二醇(EC)经常被跨性别者以达到高雌二醇水平的剂量使用.与高剂量透皮雌二醇贴剂一样，目前没有足够质量的数据能证明血栓风险的几率.另外，研究也发现高剂量 EV 注射 (10–40 mg/每两周) 导致凝血增加 (<a href="https://scholar.google.com/scholar?cluster=13464348720429057889" target="_blank" rel="noopener noreferrer">Kohli &amp; McClellan, 2001<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="http://doi.org/10.1200/jco.2004.22.90140.4726" target="_blank" rel="noopener noreferrer">Kohli et al., 2004<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1002/cncr.21528" target="_blank" rel="noopener noreferrer">Kohli, 2005<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).目前并不清楚这类短效雌二醇酯注射剂量所导致的庞大峰值是否与凝血、血栓风险有关 (<a href="https://doi.org/10.1210/jc.2017-01658" target="_blank" rel="noopener noreferrer">Hembree et al., 2017<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><p>综上所述，各种雌激素似乎会因剂量而提高血栓风险.这些研究表明在足够的雌二醇暴露下，凝血与血栓等风险是雌激素的共同特性.但是，合成与非天然雌激素持有更高的血栓风险.同时，口服雌二醇也比非口服雌二醇持有更高的风险.事实上，在女性中的生理性雌二醇水平与低–中剂量的透皮雌二醇没有明显的血栓风险.伴随着孕激素药物的使用似乎会提高雌激素带来的血栓风险，而更高剂量的孕激素药物会更大幅的提高此风险.</p><h3 id="血栓风险率" tabindex="-1"><a class="header-anchor" href="#血栓风险率" aria-hidden="true">#</a> 血栓风险率</h3><p>右表的数值主要来自观察性研究，并不是 RCTs.所以很多情况下存在着尚未确定的因果关系.另外，这些数值是具有 95%置信区间 (CI) 的概算平均数值.因此，精度与准确性在某些情况下可能较低.同时，血栓风险率会因研究以及其定义和方法而异 (包括的因素有: 抽样误差、控制混淆变量的方法、残余混杂的影响等等).</p><table><thead><tr><th style="text-align:center;">雌激素类型</th><th style="text-align:center;">血栓风险率</th></tr></thead><tbody><tr><td style="text-align:center;">口服 E2 ≤1 mg/天</td><td style="text-align:center;">1.2×</td></tr><tr><td style="text-align:center;">口服 E2 &gt;1 mg/天(A)</td><td style="text-align:center;">1.4×</td></tr><tr><td style="text-align:center;">口服 E2 ≤ 或 &gt;1 mg/天(A) + 孕(B)</td><td style="text-align:center;">1.4–1.8×</td></tr><tr><td style="text-align:center;">透皮 E2 ≤50 μg/天</td><td style="text-align:center;">0.9×</td></tr><tr><td style="text-align:center;">透皮 E2 &gt;50 μg/天(A)</td><td style="text-align:center;">1.1×</td></tr><tr><td style="text-align:center;">口服 CEEs ≤0.625 mg/天</td><td style="text-align:center;">1.4×</td></tr><tr><td style="text-align:center;">口服 CEEs &gt;0.625 mg/天(A)</td><td style="text-align:center;">1.7×</td></tr><tr><td style="text-align:center;">口服 CEEs ≤ 或 &gt;0.625 mg/天(A) + 孕(B)</td><td style="text-align:center;">1.5–2.4×</td></tr><tr><td style="text-align:center;">现代 EE + 孕 — 避孕药(C)</td><td style="text-align:center;">4.2×</td></tr><tr><td style="text-align:center;">高剂量 EE + 孕 — 避孕药(C)</td><td style="text-align:center;">高(D)</td></tr><tr><td style="text-align:center;">高剂量 PEP 注射(E)</td><td style="text-align:center;">2.1×</td></tr><tr><td style="text-align:center;">高剂量口服 DES、EE、或 EMP</td><td style="text-align:center;">5.7–10×</td></tr><tr><td style="text-align:center;">SERMs (他莫昔芬、雷洛昔芬)</td><td style="text-align:center;">~2–3×</td></tr><tr><td style="text-align:center;">怀孕 (总体) (F)</td><td style="text-align:center;">4.0×</td></tr><tr><td style="text-align:center;">怀孕 (第三期)</td><td style="text-align:center;">5.1–7.1×</td></tr><tr><td style="text-align:center;">高剂量 CPA (单独)</td><td style="text-align:center;">3–5×</td></tr></tbody></table><p>A. 一般更年期 HRT 剂量 (大约不超过双倍剂量)</p><p>B. 醋酸甲羟孕酮(MPA)、炔诺酮(NET)、Norgestrel、Drospirenone</p><p>C. 现代 EE+孕——含有 20–35 μg/天的 EE； 高剂量 EE+孕——含有 50–150 μg/天的 EE (旧时代避孕药: 60-70 年代)</p><p>D. 风险大约于现代避孕药的双倍</p><p>E. 未发表研究/分析，borderline statistical significance (95% CI 0.99–4.22)</p><p>F. 不包括产后期段.如果包括产后期，血栓风险率为 5–10× (McLintock, 2014)</p><p>Sources of the table:</p><ul><li>E2、CEEs <ul><li><a href="https://doi.org/10.1136/bmj.k4810" target="_blank" rel="noopener noreferrer">Vinogradova et al. (2019a)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Risk_of_venous_thromboembolism_with_hormone_therapy_and_birth_control_pills_(QResearch/CPRD)" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>现代 EE + 孕 (避孕药) <ul><li><a href="https://doi.org/10.1007/s11239-015-1311-6" target="_blank" rel="noopener noreferrer">Heit, Spencer, &amp; White (2016)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>高剂量 EE + 孕 (避孕药) <ul><li><a href="https://doi.org/10.1016/j.fertnstert.2016.09.027" target="_blank" rel="noopener noreferrer">PCASRM (2017)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Dose_of_ethinylestradiol_in_birth_control_pills_and_risk_of_venous_thromboembolism" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>高剂量口服 DES、EE、或 EMP <ul><li><a href="https://doi.org/10.1111/j.1464-410X.2007.06859.x" target="_blank" rel="noopener noreferrer">Seaman et al. (2007)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/j.eururo.2015.06.022" target="_blank" rel="noopener noreferrer">Klil-Drori et al. (2015)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1111/j.1464-410X.2011.10201.x" target="_blank" rel="noopener noreferrer">Ravery et al. (2011)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>SERMs (他莫昔芬、雷洛昔芬) <ul><li><a href="https://doi.org/10.1002/cncr.20347" target="_blank" rel="noopener noreferrer">Deitcher &amp; Gomes (2004)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016/j.ctrv.2011.06.009" target="_blank" rel="noopener noreferrer">Iqbal et al. (2012)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://www.sciencedirect.com/science/article/pii/B9780323462020000315" target="_blank" rel="noopener noreferrer">Konkle &amp; Sood (2019)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>怀孕 (总体) <ul><li><a href="https://doi.org/10.1007/s11239-015-1311-6" target="_blank" rel="noopener noreferrer">Heit, Spencer, &amp; White (2016)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>怀孕 (第三期) <ul><li><a href="http://dx.doi.org/10.1136/bmjopen-2015-008864" target="_blank" rel="noopener noreferrer">Sultan et al. (2015)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Venous_thromboembolism_incidence_during_pregnancy_and_the_postpartum_period" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li><li>高剂量 CPA (单独) <ul><li><a href="https://doi.org/10.1111%2Fj.1464-410X.2007.06859.x" target="_blank" rel="noopener noreferrer">Seaman et al. (2007)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016%2FS0049-3848%2810%2970035-9" target="_blank" rel="noopener noreferrer">Beyer-Westendorf et al. (2010)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1016%2FS1470-2045%2810%2970038-3" target="_blank" rel="noopener noreferrer">Van Hemelrijck et al. (2010)<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a></li></ul></li></ul><h3 id="其他因素" tabindex="-1"><a class="header-anchor" href="#其他因素" aria-hidden="true">#</a> 其他因素</h3><table><thead><tr><th style="text-align:center;">风险因素</th><th style="text-align:center;">相对风险率</th></tr></thead><tbody><tr><td style="text-align:center;">年龄</td><td style="text-align:center;">1–∞×</td></tr><tr><td style="text-align:center;">癌症</td><td style="text-align:center;">4–20×(A)</td></tr><tr><td style="text-align:center;">HIV</td><td style="text-align:center;">3–10×</td></tr><tr><td style="text-align:center;">超重/肥胖症</td><td style="text-align:center;">2–3×</td></tr><tr><td style="text-align:center;">手术、创伤、制动</td><td style="text-align:center;">5–50×</td></tr><tr><td style="text-align:center;">卧床休息</td><td style="text-align:center;">9×</td></tr><tr><td style="text-align:center;">航空旅行</td><td style="text-align:center;">1.5–3×</td></tr><tr><td style="text-align:center;">吸烟</td><td style="text-align:center;">0.8–1.5×(B)</td></tr><tr><td style="text-align:center;">静脉曲张</td><td style="text-align:center;">1–4×</td></tr><tr><td style="text-align:center;">怀孕</td><td style="text-align:center;">4×</td></tr><tr><td style="text-align:center;">产后</td><td style="text-align:center;">15–20×</td></tr></tbody></table><p>图表: 非激素性 VTE 风险因素 (<a href="http://doi.org/10.1001/archinte.160.6.809" target="_blank" rel="noopener noreferrer">Heit et al., 2000<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1182/asheducation-2005.1.1" target="_blank" rel="noopener noreferrer">Rosendaal, 2005<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1111/j.1365-2141.2010.08206.x" target="_blank" rel="noopener noreferrer">Lijfering, Rosendaal, &amp; Cannegieter, 2010<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1182/blood-2013-04-460121" target="_blank" rel="noopener noreferrer">Timp et al., 2013<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>)</p><p>A. 因癌症类型和阶段而异；乳癌与前列腺癌的风险明显较低 (Timp et al., 2013)</p><p>B. 吸烟本身与 VTE 并没有一致的关系 (Lijfering, Rosendaal, &amp; Cannegieter, 2010)</p><h2 id="非天然雌激素-肝脏代谢抗性" tabindex="-1"><a class="header-anchor" href="#非天然雌激素-肝脏代谢抗性" aria-hidden="true">#</a> 非天然雌激素: 肝脏代谢抗性</h2><p>非天然(non-bioidentical)雌激素如——EE、CEEs、DES，比口服与非口服雌二醇对肝蛋白合成造成更大的影响 (<a href="https://docdro.id/v6lPP9s" target="_blank" rel="noopener noreferrer">Kuhl, 1998<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.1080/13697130500148875" target="_blank" rel="noopener noreferrer">Kuhl, 2005<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.17925/OHR.2014.10.1.42" target="_blank" rel="noopener noreferrer">Phillips et al., 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://doi.org/10.3109/21681805.2013.861508" target="_blank" rel="noopener noreferrer">Turo et al., 2014<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; <a href="https://en.wikipedia.org/wiki/Template:Risk_of_venous_thromboembolism_with_hormone_therapy_and_birth_control_pills_(QResearch/CPRD)" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).这是因为肝脏会强烈地代谢和灭活雌二醇，而非天然雌激素由于在化学结构上与雌二醇不同，导致它们更具有肝脏代谢抗性 (<a href="https://doi.org/10.1111/jth.14626" target="_blank" rel="noopener noreferrer">Connors &amp; Middeldorp, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a> ; <a href="https://doi.org/10.3389/fendo.2019.00685" target="_blank" rel="noopener noreferrer">Swee, Javaid, &amp; Quinton, 2019<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><p>EE 可以视为一个例子.EE 的口服利用度为 45%，而口服雌二醇的为 5%；EE 的血液半衰期为 20 小时，而雌二醇的为约 1 小时.由于这种差异，EE 以一般雌激素作用而言，比雌二醇强 120 倍 (<a href="https://en.wikipedia.org/wiki/Template:Relative_oral_potencies_of_estrogens" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).因此 EE 以微克剂量(μg)使用， 而口服雌二醇则以 100 倍高的毫克剂量(mg)使用.这些差异反映 EE 对肝脏代谢强烈的抗力.</p><p>由于 EE 对肝脏代谢与灭活具有显著性的抵抗力，它能在肝脏中持续存在很长的时间——通常经过多次循环直到最终被分解.EE 拥有比口服雌二醇约 100 倍的一般效能，肝效能则约 350–1500 倍更高 (<a href="https://doi.org/10.1002/pros.2990140410" target="_blank" rel="noopener noreferrer">von Schoultz et al., 1989<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>; Kuhl, 2005).仅 1 μg/天的 EE 剂量已显示能影响肝脏代谢功能 (<a href="https://doi.org/10.1016%2Fj.gyobfe.2011.10.009" target="_blank" rel="noopener noreferrer">Trémollieres, 2012<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).此外，无论是口服、透皮、阴道给药途径都显示 EE 拥有相似的肝功能影响以及血栓风险.这表明 EE 与雌二醇不同，不需经过肝脏首过效应也能导致血栓风险.由于 EE 对代谢的抗力如此之高，无论给药途径如何，它对肝脏的影响都是巨大的.</p><ul><li><p>肝效能 (Liver potency) 比较</p><table><thead><tr><th style="text-align:center;">雌激素</th><th style="text-align:center;">相对于口服 E2</th><th style="text-align:center;">相对于透皮 E2</th></tr></thead><tbody><tr><td style="text-align:center;">透皮 E2</td><td style="text-align:center;">~0.25×(A)</td><td style="text-align:center;">1.0×(A)</td></tr><tr><td style="text-align:center;">口服 E2</td><td style="text-align:center;">1.0×</td><td style="text-align:center;">~4.0×</td></tr><tr><td style="text-align:center;">口服 CEEs</td><td style="text-align:center;">1.3–4.5×</td><td style="text-align:center;">5.2–18×</td></tr><tr><td style="text-align:center;">口服 EE</td><td style="text-align:center;">2.9–5.0×</td><td style="text-align:center;">~12–20×</td></tr><tr><td style="text-align:center;">口服 DES</td><td style="text-align:center;">5.7–7.5×</td><td style="text-align:center;">~23–30×</td></tr></tbody></table></li></ul><p>EE: 炔雌醇 (避孕药常含有的合成雌激素)</p><p>CEEs: 结合雌激素</p><p>DES: 己烯雌酚</p><p>A. 根据一项研究发现口服雌二醇拥有比透皮雌二醇在 SHBG 水平上高 4 倍的效果，当被用于产生同等 E2 水平的剂量时 (<a href="https://doi.org/10.1097%2F00042192-200007040-00006" target="_blank" rel="noopener noreferrer">Nachtigall et al., 2000<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><p>图表: 根据肝产物 (如 SHBG、其他) 得出的肝雌激素效能与雌激素一般效能的概算 (Kuhl, 2005; <a href="https://en.wikipedia.org/wiki/Template:Relative_oral_potencies_of_estrogens" target="_blank" rel="noopener noreferrer">Wiki-Table<span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span></a>).</p><ul><li>雌酮是雌激素的一种，它的激素作用非常弱.</li></ul><p>(这篇主要为某些对雌酮错误的理解做些解释)</p></div><!--[--><!--]--></div><footer class="page-meta"><div class="meta-item edit-link"><a class="external-link meta-item-label" href="https://github.com/BBleae/hrt-book/edit/main/docs/parts/Part2.md" rel="noopener noreferrer" target="_blank" aria-label="编辑本页面"><!--[--><!--]--> 编辑本页面 <span><svg class="external-link-icon" xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path><polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg><span class="external-link-icon-sr-only">open in new window</span></span><!--[--><!--]--></a></div><!----><div class="meta-item contributors"><span class="meta-item-label">贡献者: </span><span class="meta-item-info"><!--[--><!--[--><span class="contributor" title="email: KiritaniAyaka@users.noreply.github.com">Ayaka</span><!----><!--]--><!--]--></span></div></footer><!----><!--[--><!--]--></main><!--]--></div><!----><!--]--></div>
    <script type="module" src="/assets/app-ab70e89e.js" defer=""></script>
  

</body></html>
